Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, it is hereby informed that the Board of Directors at their meeting held on today i.e. ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved standalone and consolidated unaudited financial results for Q3 FY26 and nine months ended December 31, 2025. On a standalone basis, revenue from operations rose to ₹2,213.66 lakhs in Q3 (vs ₹1,870.02 lakhs in Q3 FY25, ~18% YoY) and ₹5,517.80 lakhs for 9M FY26 (vs ₹4,893.14 lakhs, ~13% YoY). Standalone profit after tax jumped to ₹86.24 lakhs in Q3 (vs ₹46.10 lakhs, ~87% YoY) and ₹160.25 lakhs for 9M (vs ₹90.88 lakhs, ~76% YoY). Consolidated revenue was ₹5,194.36 lakhs for Q3 and ₹14,294.96 lakhs for 9M, with consolidated PAT of ₹132.63 lakhs and ₹294.55 lakhs respectively. The auditor (NYS & Company) issued an unmodified limited review report with no qualifications. The company also disclosed utilization of ₹2,481.20 lakhs raised via a rights issue in November 2025, allocated mainly to working capital (₹1,800.34 lakhs) and debt repayment (₹85 lakhs).
Strong standalone profit growth signals improving margins and operational efficiency, which is positive for shareholders. However, the recently concluded rights issue doubled the paid-up equity share capital (from ₹2,481.20 to ₹4,962.40 lakhs) at face value with no premium, which will dilute earnings per share going forward despite the healthy bottom-line growth.